Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer

M Dutt; G Hartel; RS Richards; AK Shah; A Mohamed; S Apostolidou; A Gentry-Maharaj; JD Hooper; LC Perrin; U Menon; MM Hill

Journal article

Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer

M Dutt, G Hartel, RS Richards, AK Shah, A Mohamed, S Apostolidou, A Gentry-Maharaj, JD Hooper, LC Perrin, U Menon, MM Hill

Proteomics Clinical Applications | WILEY-V C H VERLAG GMBH | Published : 2023

DOI: 10.1002/prca.202200114

Abstract

Purpose: This study aimed to identify serum glycoprotein biomarkers for early detection of high-grade serous ovarian cancer (HGSOC), the most common and aggressive histotype of ovarian cancer. Experimental design: The glycoproteomics pipeline lectin magnetic bead array (LeMBA)-mass spectrometry (MS) was used in age-matched case-control serum samples. Clinical samples collected at diagnosis were divided into discovery (n = 30) and validation (n = 98) sets. We also analysed a set of preclinical sera (n = 30) collected prior to HGSOC diagnosis in the UK Collaborative Trial of Ovarian Cancer Screening. Results: A 7-lectin LeMBA-MS/MS discovery screen shortlisted 59 candidate proteins and three l..

View full abstract

University of Melbourne Researchers

Mriga Dutt Author

Related Projects (3)

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

Grants

Awarded by University College London Hospitals Biomedical Research Centre

Funding Acknowledgements

Ovarian Cancer Research Foundation (Australia), Grant/Award Number: GA-2018-04; Medical Research Council, Grant/Award Numbers: G9901012, G0801228; Peter MacCallum Foundation, Grant/Award Number: N/A; MRC core funding for MRC CTU, Grant/Award Number: MC_UU_00004/01; UK Department of Health and Social Care, Grant/Award Number: N/A; Cancer Research UK, Grant/Award Number: C1479/A2884; Ovarian Cancer Australia; The Eve Appeal; The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia, Grant/Award Numbers: 191,211,182; NIHR University College London Hospitals Biomedical Research Centre, Grant/Award Number:N/A; QIMR Berghofer Medical Research Institute, Grant/Award Number:N/A; Medical Research and Materiel Command, Grant/Award Number: DAMD17-01-1-0729; National Health and Medical Research Council, Grant/Award Numbers: ID199600, ID400281, ID400413